Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
Escalation phase (4-8mg): This is where management becomes important
PET tracers showed that cancer cells rely heavily on glutamine uptake via mTORC1 signaling, while myeloid cells in the TME are more dependent on glucose, as are T cells and cancer cells (but to a lesser extent) 128
NHS availability is subject to a NICE appraisal
US$ 24.57
-1775582746855.png&w=3840&q=75)
US$ 28.94
US$ 24.06
US$ 25.55
US$ 25.66
